ArticleAmerican journal of hematology2023
Venous thromboembolism mortality and trends in older US adults, 2011-2019.
Article in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis.Cardiovascular drugs and therapy · 2026Pooled it
- Pooled it
- Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism.Nature reviews. Cardiology · 2026Review
- IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?Journal of thrombosis and thrombolysis · 2026Review
- Comparative Effectiveness of Oral Anticoagulants and Home Time After Venous Thromboembolism in Frail and Non-Frail Older Adults.American journal of hematology · 2026Article
- Endothelial Cell-Specific Molecule-1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pharmacoequity in Anticoagulation Among Medicare Patients With Venous Thromboembolism.JAMA network open · 2025Article
- Evaluation of factors underlying differences in venous thromboembolism rates between Black and White patients.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
- Deep vein thrombosis in Ethiopia: a systematic review and meta-analysis, 2025.Thrombosis journal · 2025Review
- Frailty and risk of venous thromboembolism in older adults: the Atherosclerosis Risk in Communities Study.Journal of thrombosis and haemostasis : JTH · 2025Article
- Predicting inferior vena cava filter complications using machine learning.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States county.Research and practice in thrombosis and haemostasis · 2024Article
- Venous Thromboembolism Management throughout the COVID-19 Era: Addressing Acute and Long-Term Challenges.Journal of clinical medicine · 2024Article
- Article
- Blood urea nitrogen to creatinine ratio is associated with in-hospital mortality in critically ill patients with venous thromboembolism: a retrospective cohort study.Frontiers in cardiovascular medicine · 2024Article
- Comparison of clinical outcomes of venous thromboembolic disease between outpatient and inpatient management.Archivos peruanos de cardiologia y cirugia cardiovascularArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) affects 1.2 million people per year in the United States. With several clinical changes in diagnosis and treatment approaches in the past decade, we evaluated contemporary post-VTE mortality risk profiles and trends. Incident VTE cases were identified from the 2011-2019 Medicare 20% Sample, which is representative of nearly all Americans aged 65 and older. The social deprivation index was linked from public data; race/ethnicity and sex were self-reported. The all-cause mortality risk 30 days and 1 year after incident VTE was calculated in demographic subgroups and by prevalent cancer diagnosis status using model-based standardization. Risks for major cancer types, risk differences by age, sex, race/ethnicity, and socio-economic status (SES), and trends over time are also reported. The all-cause mortality risk among older US adults following incident VTE was 3.1% (95% CI 3.0-3.2) at 30 days and 19.6% (95% CI 19.2-20.1) at 1 year. For cancer-related VTE events, the age-sex-race-standardized risk was 6.0% at 30 days and 34.7% at 1 year. The standardized 30-day and 1-year risks were higher among non-White beneficiaries and among those with low SES. One-year mortality risk decreased 0.28 percentage points per year (95% CI 0.16-0.40) on average across the study period, with no trend observed for 30-day mortality risk. In sum, all-cause mortality risk following incident VTE has decreased slightly in the last decade, but racial and socio-economic disparities persist. Understanding patterns of mortality among demographic subgroups and in cancer-associated events is important for targeting efforts to improve VTE management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.